Page last updated: 2024-10-24

neuropeptide processing

Definition

Target type: biologicalprocess

Any protein maturation process achieved by the cleavage of a peptide bond or bonds within a neuropeptide precursor. Processing leads to the attainment of the full functional capacity of the neuropeptide. [PMID:12657671, PMID:17564681]

Neuropeptide processing is a complex and highly regulated process that involves the synthesis, cleavage, and modification of precursor proteins into biologically active peptides. This process ensures the precise generation of functional neuropeptides that play crucial roles in regulating a wide range of physiological functions, including neurotransmission, hormone release, and behavior.

1. **Gene Transcription and Translation:** The process begins with the transcription of neuropeptide precursor genes into messenger RNA (mRNA). mRNA is then translated into a precursor protein, known as a prohormone or proneuropeptide, by ribosomes in the cytoplasm of neurons.

2. **Sorting and Targeting:** Prohormones are sorted and targeted to the appropriate cellular compartments for further processing. They are typically packaged into secretory vesicles, which are small membrane-bound organelles responsible for storing and transporting neuropeptides.

3. **Cleavage by Prohormone Convertases:** Once in secretory vesicles, prohormones undergo enzymatic cleavage by a family of proteases called prohormone convertases (PCs). PCs are highly specific enzymes that recognize and cleave specific amino acid sequences within prohormones. The cleavage process generates individual neuropeptides, often along with other peptides and inactive fragments.

4. **Post-Translational Modifications:** Following cleavage, neuropeptides undergo various post-translational modifications that are essential for their biological activity. These modifications include:
- **Amidation:** The C-terminal amino acid of many neuropeptides is amidated, which increases their stability and potency.
- **Glycosylation:** The addition of sugar molecules can influence neuropeptide solubility, stability, and receptor binding.
- **Phosphorylation:** The addition of phosphate groups can regulate neuropeptide activity and signaling pathways.
- **Acetylation:** The addition of an acetyl group to the N-terminal amino acid can enhance neuropeptide stability and function.

5. **Storage and Release:** Processed neuropeptides are stored within secretory vesicles until they are signaled for release. Upon receiving a neuronal stimulus, the vesicles fuse with the cell membrane and release their cargo into the synaptic cleft or extracellular space.

6. **Neuropeptide Activity:** Released neuropeptides bind to specific receptors on target cells, initiating a cascade of intracellular signaling events that ultimately lead to physiological responses. These responses can range from altering ion channel permeability to modulating gene expression, depending on the neuropeptide and its receptor.

7. **Regulation and Degradation:** The activity of neuropeptides is tightly regulated to ensure proper function. Neuropeptides can be rapidly inactivated by enzymatic degradation or reuptake into the presynaptic neuron. Degradation is often catalyzed by peptidases, which break down neuropeptides into inactive fragments.

Neuropeptide processing is a highly intricate and essential process for the proper functioning of the nervous system and the maintenance of various physiological processes. It is a target for drug development, as manipulating the processing of neuropeptides can potentially alter their activity and provide therapeutic benefits for a range of neurological and endocrine disorders.'
"

Proteins (1)

ProteinDefinitionTaxonomy
NeprilysinA neprilysin that is encoded in the genome of human. [PRO:WCB, UniProtKB:P08473]Homo sapiens (human)

Compounds (18)

CompoundDefinitionClassesRoles
thiorphanThiorphan: A potent inhibitor of membrane metalloendopeptidase (ENKEPHALINASE). Thiorphan potentiates morphine-induced ANALGESIA and attenuates naloxone-precipitated withdrawal symptoms.N-acyl-amino acid
losartanlosartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position

Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
biphenylyltetrazole;
imidazoles
angiotensin receptor antagonist;
anti-arrhythmia drug;
antihypertensive agent;
endothelin receptor antagonist
captoprilcaptopril : A L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug.

Captopril: A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.
alkanethiol;
L-proline derivative;
N-acylpyrrolidine;
pyrrolidinemonocarboxylic acid
antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
sq 28603SQ 28603: a selective neutral endopeptidase inhibitor
kelatorphankelatorphan: inhibitor of enkephalin metabolism; structure given in first source
(3-(n-hydroxy)carboxamido-2-benzylpropanoyl)glycine
2-(4-morpholinyl)-4h-1-benzopyran-4-one2-(4-morpholinyl)-4H-1-benzopyran-4-one: an aminochromone; exhibits both antiproliferative and antichemotactic activity in vitro
cgs 26303CGS 26303: a potent non-peptidic inhibitor of neutral endopeptidase capable of protecting atrial natriuretic peptide from enzymatic degradation; structure given in first source
bb3497BB3497: peptide deformylase inhibitor; structure in first source
candoxatrilatcandoxatrilat : A dicarboxylic acid monoamide obtained by formal condensation between the amino group of cis-4-aminocyclohexanecarboxylic acid and the cyclopentanecarboxylic acid group of 1-[(2S)-2-carboxy-3-(2-methoxyethoxy)propyl]cyclopentanecarboxylic acid. A potent inhibitor of neutral endopeptidase (NEP, neprilysin, EC 3.4.24.11), it is used as its 2,3-dihydro-1H-inden-5-yl ester prodrug in the treatment of chronic heart failure.

candoxatrilat: USAN lists candoxatrilat (UK-73,967) with RN 123122-54-3
actinoninactinonin: natural hydroxamic acid, pseudopeptide antibiotic isolated from Streptomyces species; structure
phosphoramidonphosphoramidon : A dipeptide isolated from the cultures of Streptomyces tanashiensis.

phosphoramidon: a membrane metallo-endopeptidase & endothelin-converting enzyme inhibitor; thermolysin inhibitor from culture filtrate of Streptomyces tanashiensis; structure
deoxyaldohexose phosphate;
dipeptide
bacterial metabolite;
EC 3.4.24.11 (neprilysin) inhibitor;
EC 3.4.24.71 (endothelin-converting enzyme 1) inhibitor
omapatrilatomapatrilat: structure in first sourcedipeptide
sitagliptinsitagliptin : A triazolopyrazine that exhibits hypoglycemic activity.triazolopyrazine;
trifluorobenzene
EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
environmental contaminant;
hypoglycemic agent;
serine proteinase inhibitor;
xenobiotic
thiorphan
uk 81,252sampatrilat: structure in first source
cgs 35066CGS 35066: an endothelin-converting enzyme-1 inhibitor; structure in first source
quininibquininib : A styrylquinoline that is trans-2-styrylquinoline in which the the phenyl group has been substituted at position 2 by a hydroxy group. It is an anti-angiogenic compound that exerts a dose-dependent antagonism of the cysteinyl leukotriene pathway, preferentially antagonising cysteinyl leukotriene receptor 1. The major species at pH 7.3

quininib: has antiangiogenic activity; structure in first source
phenols;
styrylquinoline
angiogenesis inhibitor